PFIZER INC. news, videos and press releases - Page 6
For more news please use our advanced search feature.
PFIZER INC. - More news...
PFIZER INC. - More news...
- Pfizer Invites Public to View and Listen to Webcast of May 3 Conference Call with Analysts
- Pfizer to Supply UNICEF up to 4 Million Treatment Courses of Novel COVID-19 Oral Treatment for Low- and Middle-Income Countries
- Pfizer Completes Acquisition of Arena Pharmaceuticals
- Pfizer Initiates Phase 2/3 Study of Novel COVID-19 Oral Treatment in Pediatric Participants
- Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
- Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus (RSV) Vaccine Candidate for the Prevention of RSV in Infants from Birth up to Six Months of Age by Active Immunization of Pregnant Women
- Phase 3 CLOVER Trial for Pfizer’s Investigational Clostridioides Difficile Vaccine Indicates Strong Potential Effect in Reducing Duration and Severity of Disease Based on Secondary Endpoints
- Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
- Pfizer Invites Public to View and Listen to Webcast of Pfizer Keynote Presentation at Healthcare Conference
- Pfizer and OPKO’s Once-Weekly NGENLA™ (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency
- European Medicines Agency Approves Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease and Pneumonia in Adults
- Pfizer and BioNTech Provide Update on Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age
- Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
- Pfizer Reports Fourth-Quarter and Full-Year 2021 Results
- Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request From U.S. FDA
- Pfizer Announces New Chief Development Officer
- European Commission Approves LORVIQUA® (lorlatinib) as a First-Line Treatment for ALK-Positive Advanced Lung Cancer
- Pfizer Receives CHMP Positive Opinion for Novel COVID-19 Oral Treatment
- Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age
- Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency
- U.S. FDA Approves Pfizer’s CIBINQO® (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis
- Positive Top-Line Results of Pfizer’s Phase 3 Study Exploring Coadministration of PREVNAR 20™ With Pfizer-BioNTech COVID-19 Vaccine in Older Adults Released
- Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics
- Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases
- Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine
- Pfizer to Provide U.S. Government with an Additional 10 Million Treatment Courses of its Oral Therapy to Help Combat COVID-19
- Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
- Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older
- Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
- Pfizer Invites Public to View and Listen to Webcast of February 8 Conference Call with Analysts
